MX2007004276A - 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1. - Google Patents

1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1.

Info

Publication number
MX2007004276A
MX2007004276A MX2007004276A MX2007004276A MX2007004276A MX 2007004276 A MX2007004276 A MX 2007004276A MX 2007004276 A MX2007004276 A MX 2007004276A MX 2007004276 A MX2007004276 A MX 2007004276A MX 2007004276 A MX2007004276 A MX 2007004276A
Authority
MX
Mexico
Prior art keywords
azolidinones
naphthyridine
antiproliferative activity
cdk1
cdk1 antiproliferative
Prior art date
Application number
MX2007004276A
Other languages
English (en)
Inventor
Jin-Jun Liu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2007004276A publication Critical patent/MX2007004276A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invencion se refiere a las 1,5-naftiridin-azolidinonas de la formula (I) a los procesos para la fabricacion de dichos compuestos, asi como los medicamentos que los contienen. Estos compuestos soninhibidores de CDKl y muestran actividad antiproliferativa. Estos son por lo tanto Utiles como agentes anti-cancerosos.
MX2007004276A 2004-10-14 2005-10-05 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1. MX2007004276A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61880704P 2004-10-14 2004-10-14
PCT/EP2005/010716 WO2006040052A1 (en) 2004-10-14 2005-10-05 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity

Publications (1)

Publication Number Publication Date
MX2007004276A true MX2007004276A (es) 2007-05-16

Family

ID=36013291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004276A MX2007004276A (es) 2004-10-14 2005-10-05 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1.

Country Status (11)

Country Link
US (1) US7268231B2 (es)
EP (1) EP1805174A1 (es)
JP (1) JP2008516905A (es)
KR (2) KR100875408B1 (es)
CN (1) CN101039944B (es)
AU (1) AU2005293835A1 (es)
BR (1) BRPI0516488A (es)
CA (1) CA2583192A1 (es)
MX (1) MX2007004276A (es)
RU (1) RU2405781C2 (es)
WO (1) WO2006040052A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
TW200745066A (en) 2005-09-16 2007-12-16 Torrent Pharmaceuticals Ltd Novel PTP1B inhibitors
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
CN101555248B (zh) * 2009-05-22 2011-06-22 北京欧凯纳斯科技有限公司 一种多取代1,5-萘啶化合物的制备方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
RU2521390C1 (ru) * 2013-03-14 2014-06-27 Общество с ограниченной ответственностью "Тиацен" Производное роданина и средство для профилактики опухолевых заболеваний
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PT3122358T (pt) 2014-03-26 2021-03-04 Astex Therapeutics Ltd Combinações de inibidores do fgfr e cmet para o tratamento do cancro
DK3122359T3 (da) 2014-03-26 2021-03-08 Astex Therapeutics Ltd Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2996989C (en) 2015-09-23 2023-10-03 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
LT3353177T (lt) 2015-09-23 2020-08-25 Janssen Pharmaceutica Nv Tricikliniai heterociklai, skirti vėžio gydymui
JP7311620B2 (ja) 2019-03-08 2023-07-19 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのコリメータおよびエネルギーデグレーダ
US20230167104A1 (en) * 2020-04-30 2023-06-01 Perha Pharmaceuticals New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
EP3904354A1 (en) * 2020-04-30 2021-11-03 Perha Pharmaceuticals New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
TW202237585A (zh) 2020-11-27 2022-10-01 瑞士商瑞森製藥公司 Ｃｄｋ抑制劑
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
EP4173674A1 (en) 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1681811B (zh) * 2002-07-10 2010-05-26 默克雪兰诺有限公司 唑烷酮-乙烯基稠合的-苯衍生物
SI1567112T1 (sl) * 2002-11-22 2009-02-28 Smithkline Beecham Corp Thiazolidin-4-oni za inhibiranje proteinov hyak3

Also Published As

Publication number Publication date
AU2005293835A1 (en) 2006-04-20
CN101039944A (zh) 2007-09-19
US7268231B2 (en) 2007-09-11
US20060084673A1 (en) 2006-04-20
JP2008516905A (ja) 2008-05-22
RU2405781C2 (ru) 2010-12-10
RU2007117765A (ru) 2008-11-20
KR100875408B1 (ko) 2008-12-23
CA2583192A1 (en) 2006-04-20
BRPI0516488A (pt) 2008-09-09
EP1805174A1 (en) 2007-07-11
CN101039944B (zh) 2010-05-05
KR20070053332A (ko) 2007-05-23
KR20080075235A (ko) 2008-08-14
WO2006040052A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
MX2007004276A (es) 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1.
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
TW200800999A (en) Novel compounds
WO2004074244A3 (en) Pyrimidine compounds
TW200801003A (en) Novel compounds
SE0301700D0 (sv) Novel compounds
TW200738659A (en) Novel compounds
IL180722A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
AU2003228770A8 (en) Substituted pyrazolopyrimidines
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
SE0302811D0 (sv) Novel compounds
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
ATE458485T1 (de) Ubiquitin-ligase-hemmer und verwandte verfahren
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
WO2007120333A3 (en) Tetracyclic kinase inhibitors
TW200745084A (en) Novel compounds
TW200635917A (en) Novel compounds
DE602006020295D1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
MX2007004273A (es) Nuevas azaindol-tiazolinonas como agentes anti-cancerosos.

Legal Events

Date Code Title Description
FG Grant or registration